613
Participants
Start Date
September 16, 2021
Primary Completion Date
August 5, 2025
Study Completion Date
August 5, 2025
Pembrolizumab/Vibostolimab Co-Formulation
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Pembrolizumab
Pembrolizumab 200 mg administered via IV infusion Q3W.
Lenvatinib
Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
5-Fluorouracil
5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
Cisplatin
Cisplatin administered via IV infusion
Paclitaxel
Paclitaxel administered via IV infusion at investigator's choice of dose
Gemcitabine
Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
Carboplatin
Carboplatin administered via IV infusion at investigator's choice of dose and frequency
Docetaxel
For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
Bevacizumab
Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
Capecitabine
Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
Oxaliplatin
Oxaliplatin administered via IV infusion Q3W up to 35 cycles
Chang Gung Medical Foundation-Linkou Branch ( Site 1304), Taoyuan District
NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302), Tainan City
National Taiwan University Hospital-Oncology ( Site 1301), Taipei
Memorial Sloan Kettering Cancer Center ( Site 1002), New York
Mackay Memorial Hospital ( Site 1305), Taipei
Memorial Sloan Kettering - Westchester ( Site 1020), Harrison
Memorial Sloan Kettering - Nassau ( Site 1026), Uniondale
Memorial Sloan Kettering- Commack ( Site 1021), Commack
Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171), Berlin
Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138), Rozzano
Ospedale San Raffaele-Oncologia Medica ( Site 1135), Milan
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (, Milan
Centre Georges François Leclerc ( Site 1155), Dijon
Trakya University-Medical Oncology ( Site 1207), Edirne
Clinica Universidad de Navarra-Medical Oncology ( Site 1118), Madrid
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111), Madrid
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117), Pozuelo de Alarcón
Istanbul Universitesi Cerrahpasa ( Site 1203), Istanbul- Fatih
Institut Regional du Cancer Montpellier ( Site 1157), Montpellier
Acibadem Universitesi Atakent Hastanesi ( Site 1208), Istanbul
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204), Istanbul
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172), Düsseldorf
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114), Seville
Karmanos Cancer Institute ( Site 1007), Detroit
Sanford Cancer Center-Gynecologic Oncology ( Site 1015), Sioux Falls
Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180), Heidelberg
Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne, Tübingen
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024), Tulsa
Institut Curie ( Site 1152), Paris
Houston Methodist Hospital ( Site 1017), Houston
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134), Napoli
Klinikum der Universität München Großhadern ( Site 1176), München
Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156), Avignon
City of Hope Comprehensive Cancer Center ( Site 1001), Duarte
Gustave Roussy-medicine departement ( Site 1153), Villejuif
Alaska Womens Cancer Care ( Site 1016), Anchorage
Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425), Bogotá
Oncologos del Occidente ( Site 1424), Pereira
Fundación Cardiovascular de Colombia ( Site 1423), Piedecuesta
Rambam Health Care Campus-Oncology ( Site 1141), Haifa
James Lind Centro de Investigacion del Cancer ( Site 1404), Temuco
Sheba Medical Center-ONCOLOGY ( Site 1144), Ramat Gan
Sourasky Medical Center-Oncology ( Site 1143), Tel Aviv
FALP-UIDO ( Site 1401), Santiago
Oncovida ( Site 1405), Santiago
Bradfordhill-Clinical Area ( Site 1402), Santiago
Hadassah Medical Center-Oncology ( Site 1142), Jerusalem
University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente, Orange
Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge
Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051), Kingston
Princess Margaret Cancer Centre ( Site 1056), Toronto
Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422), Medellín
Clinica de la Costa S.A.S. ( Site 1421), Barranquilla
CENTRE LEON BERARD-Medical oncology ( Site 1151), Lyon
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136), Rome
Aichi Cancer Center Hospital ( Site 1324), Nagoya
National Cancer Center Hospital East ( Site 1321), Kashiwa
Osaka International Cancer Institute ( Site 1323), Osaka
National Cancer Center Hospital ( Site 1322), Tokyo
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121), Amsterdam
Erasmus Medisch Centrum-Medical Oncology ( Site 1122), Rotterdam
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101, Warsaw
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103), Gdansk
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104), Koszalin
Seoul National University Hospital-Internal Medicine ( Site 1312), Seoul
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311), Seoul
Asan Medical Center ( Site 1313), Seoul
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113), Hospitalet
Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201), Adana
Hacettepe Universitesi-oncology hospital ( Site 1209), Ankara
Ankara City Hospital-Medical Oncology ( Site 1202), Ankara
Merck Sharp & Dohme LLC
INDUSTRY